Expert Video - How is lower-risk MDS treated?
MDS experts, Dr Alan List and Dr David Sallman, explain that the goals of therapy for patients with lower-risk myelodysplastic syndromes (MDS) are to improve blood counts and alleviate symptoms. The treatment options for lower-risk MDS discussed are: recombinant erythropoietin, lenalidomide, immunosuppressive therapy, and hypomethylating agents. They also discuss watchful waiting if a patient with lower-risk MDS has no symptoms or doesn’t have very low blood cell counts.
Click here to take our SURVEY
Your feedback is important to us! We will use your feedback to develop future areas of content about MDS which will help other patients, caregivers and families.
Other Modules:
Animation - Management and Treatment of MDS
Slide Show - Management and Treatment of MDS
1.
What are the treatment options for MDS?
2.
How is lower-risk MDS treated?
3.
How is higher-risk MDS treated?
4.
What is supportive care for MDS?
5.
Are vitamin supplements beneficial for MDS treatment?
6.
What are erythropoietin-stimulating agents (ESAs)?
7.
What is cytotoxic chemotherapy and when is it used for MDS?
8.
What is lenalidomide and when is it used for MDS?
9.
What are hypomethylating agents and when are they used for MDS?
10.
How long will MDS treatment be given?
11.
What is immunosuppressive therapy and when is it used for MDS?
12.
What other options are there if first-line MDS treatment doesn’t work?
13.
David's story: How was your MDS initially treated?
